Expertise in
61
conditions

Dr. Mehmet S. Copur

Oncology
St. Francis Medical Plaza
2116 W Faidley Ave, 
Grand Island, NE 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
44 Years of Experience
Expertise in
61
conditions
St. Francis Medical Plaza
2116 W Faidley Ave, 
Grand Island, NE 

Overview

Mehmet Copur is an Oncologist practicing medicine in Grand Island, Nebraska. He has been practicing medicine for over 44 years.

Dr. Copur is highly rated in 61 conditions, according to our data. His clinical expertise encompasses Colorectal Cancer, Breast Cancer, Lynch Syndrome, Bone Marrow Aspiration, and Pancreatectomy.

He is actively involved in clinical research, co-authoring 74 peer reviewed articles and participating in 102 clinical trials. Dr. Copur is currently accepting new patients.

Graduate Year

1982

Specialties

Oncology

Licenses

Internal Medicine in NE

Hospital Affiliations

York General Health Care Services
Thayer County Health Services
Mary Lanning Healthcare
The Nebraska Medical Center
Grand Island Regional Medical Center

Languages Spoken

English
Turkish

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medica
  • EPO
  • HMO
  • PPO
Northern Plains Alliance
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE PDP
Oscar
  • EPO
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 7 Less Insurance Carriers -

Locations

St. Francis Medical Plaza
2116 W Faidley Ave, Grand Island, NE 68803

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

102 Clinical Trials

Phase II Trial of SMO/ AKT/ NF2/CDK Inhibitors in Progressive Meningiomas With SMO/ AKT/ NF2/CDK Pathway Mutations
Phase II Trial of SMO/ AKT/ NF2/CDK Inhibitors in Progressive Meningiomas With SMO/ AKT/ NF2/CDK Pathway Mutations
Enrollment Status: Recruiting
Publish Date: September 02, 2026
Intervention Type: Drug
Study Drugs: Vismodegib, GSK2256098, Capivasertib, Abemaciclib
Study Phase: Phase 2
Colorectal Cancer Metastatic dMMR/MSI-H Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab/Atezolizumab Combination Versus Single Agent Atezolizumab in the First-Line Treatment of Patients With Deficient DNA Mismatch Repair (dMMR)/Microsatellite Instability-High (MSI-H) Metastatic Colorectal Cancer
Colorectal Cancer Metastatic dMMR/MSI-H Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab/Atezolizumab Combination Versus Single Agent Atezolizumab in the First-Line Treatment of Patients With Deficient DNA Mismatch Repair (dMMR)/Microsatellite Instability-High (MSI-H) Metastatic Colorectal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 08, 2026
Intervention Type: Other, Procedure, Drug, Biological
Study Phase: Phase 3
A Phase II Trial of Trametinib With Docetaxel in Patients With KRAS Mutation Positive Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease Following One or Two Prior Systemic Therapies
A Phase II Trial of Trametinib With Docetaxel in Patients With KRAS Mutation Positive Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease Following One or Two Prior Systemic Therapies
Enrollment Status: Active_not_recruiting
Publish Date: September 04, 2026
Intervention Type: Other, Drug
Study Drugs: Docetaxel, Trametinib
Study Phase: Phase 2
Tomosynthesis Mammographic Imaging Screening Trial (TMIST)
Tomosynthesis Mammographic Imaging Screening Trial (TMIST)
Enrollment Status: Active_not_recruiting
Publish Date: September 04, 2026
Intervention Type: Other, Procedure
Study Phase: Phase 3
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
Enrollment Status: Terminated
Publish Date: September 04, 2026
Intervention Type: Other, Drug
Study Drug: Aspirin
Study Phase: Phase 3
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women With Early Breast Cancer
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women With Early Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 02, 2026
Intervention Type: Other
Study Phase: Phase 3
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: August 31, 2026
Intervention Type: Other, Radiation, Procedure, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 3
A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: August 31, 2026
Intervention Type: Radiation, Procedure
Study Phase: Phase 3
DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) a Phase III Trial
DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) a Phase III Trial
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Procedure, Biological, Drug
Study Drugs: Dabrafenib Mesylate, Ipilimumab, Nivolumab, Trametinib Dimethyl Sulfoxide
Study Phase: Phase 3
A Randomized Phase II Trial of Tamoxifen Versus Z-Endoxifen HCL in Postmenopausal Women With Metastatic Estrogen Receptor Positive, HER2 Negative Breast Cancer
A Randomized Phase II Trial of Tamoxifen Versus Z-Endoxifen HCL in Postmenopausal Women With Metastatic Estrogen Receptor Positive, HER2 Negative Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Drug
Study Drugs: Endoxifen Hydrochloride, Tamoxifen Citrate
Study Phase: Phase 2
View 9 Less Clinical Trials

73 Total Publications

Investigating the Efficacy and Safety of a Dose-Dense Paclitaxel, Cyclophosphamide With Trastuzumab in Stage I-II Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer.
Investigating the Efficacy and Safety of a Dose-Dense Paclitaxel, Cyclophosphamide With Trastuzumab in Stage I-II Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer.
Journal: Clinical breast cancer
Published: May 09, 2024
Similar Doctors
Expertise in
37
conditions
Expertise in
37
conditions
Referral may be required

Fred & Pamela Buffett Cancer Center - Kearney

2232 Chancellors Ave, 
Kearney, NE 
 (44.2 miles away)
308-865-2303
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Cynthia Lewis is an Oncologist practicing medicine in Kearney, Nebraska. Dr. Lewis is highly rated in 37 conditions, according to our data. Her clinical expertise encompasses Paget Disease of the Breast, Colorectal Cancer, Lynch Syndrome, Familial Colorectal Cancer, and Bone Marrow Aspiration. Dr. Lewis is currently accepting new patients.

Expertise in
39
conditions
Expertise in
39
conditions
Referral may be required

Fred & Pamela Buffett Cancer Center - Kearney

2232 Chancellors Ave, 
Kearney, NE 
 (44.2 miles away)
308-865-2303
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Nick Hartl is an Oncologist practicing medicine in Kearney, Nebraska. Dr. Hartl is highly rated in 39 conditions, according to our data. His clinical expertise encompasses Chronic Lymphocytic Leukemia (CLL), Pleuropulmonary Blastoma, Lung Cancer, Paget Disease of the Breast, and Bone Marrow Aspiration. Dr. Hartl is currently accepting new patients.

Expertise in
11
conditions
Expertise in
11
conditions
Referral may be required

Saint Francis Cancer Treatment Center

2620 W Faidley Ave, 
Grand Island, NE 
 (0.3 miles away)
308-398-5450
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Jami Kezeor is an Oncologist practicing medicine in Grand Island, Nebraska. Dr. Kezeor is highly rated in 11 conditions, according to our data. Her clinical expertise encompasses Lynch Syndrome, Colorectal Cancer, Familial Colorectal Cancer, and Richter Syndrome. Dr. Kezeor is currently accepting new patients.

Frequently Asked Questions about Dr. Mehmet S. Copur

How do I make an appointment with Dr. Mehmet S. Copur?

You can book an appointment with Dr. Mehmet S. Copur by calling their office at 308-398-5450. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Mehmet S. Copur a top-rated expert for Colorectal Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Mehmet S. Copur is classified as an Distinguished expert for Colorectal Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Mehmet S. Copur specialize in?

While Dr. Mehmet S. Copur is a Oncology, they have specific expertise in Colorectal Cancer, Breast Cancer, and Lynch Syndrome. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Mehmet S. Copur participate in research or clinical trials?

Yes. Dr. Mehmet S. Copur has published 73 articles and abstracts on conditions like Colorectal Cancer. You can view a list of Dr. Mehmet S. Copur's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Mehmet S. Copur accept my insurance?

Dr. Mehmet S. Copur accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 308-398-5450 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Copur's expertise for a condition
ConditionClose
    View All 18 Distinguished Conditions
    View All 43 Advanced Conditions
    View All 87 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile